European Union – Information. The applicant companies, part of the Merck group of companies, had been granted a marketing authorisation (MA) for Bravecto, a veterinary medicinal product for the treatment of tick and flea infestation in dogs. The applicants subsequently sought, pursuant to Regulation (EC) No 1049/2001, annulment of the European Commission's decision to give a third party access to the toxology reports contained in the Bravecto file. The General Court of the European Union dismissed the applicants' action on the basis that the pleas they had relied on could not be justified for the purposes of art 4 of that regulation.